Trial Profile
Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Bicalutamide; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms POSEIDON
- Sponsors Ipsen
- 31 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 29 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.